Latest Articles“Encourage pediatric drugs catalogue(batches 1 - 3)” have been issued by National Health Commission to facilitate the development and accessibility of paediatric medicines. The indications, approval dosage form and reference list drug(RLD) of chemical psychotropic and neuropsychiatric drugs in this catalogue are sorted out. Based on the analysis of specific cases and relevant review reports, some key points of the drug research and development are discussed, and some considerations about pharmaceutical studies are put forward in order to provide certain references for the selected pediatric drugs. It's recommended to take clinical needs into account and conduct further in-depth pharmaceutical studies on dosage form, drug substance and quality control, so as to improve the development of pediatric drugs.
In recent years, China has frequently issued relevant regulations and guiding principles to encourage the development of drugs for children. However, due to the specificity of children, developing child-friendly excipients is a challenge, especially in choosing appropriate excipients for pediatric medicines. In particular, the selection of appropriate excipients for pediatric medicines is often limited due to the lack of safety data. In this paper, the closely concerned antimicrobial agents were taken as an example, and the relevant regulations and technical requirements of China, WHO, EMA, and other authoritative regulatory authorities were sorted out, and the problems that antimicrobial agents for pediatric medicine need to pay attention to and the differences between pediatric medicine and adult drugs and related registration and application requirements were summarized to help drug researchers develop more suitable drugs for pediatric.
Due to the physiological characteristic of the pediatric population, extrapolation of clinical data from the adult population to the pediatric population is a development focus on pediatric medication. Bayesian statistics, as a flexible method to efficiently utilize the occupied early clinical data, is becoming a powerful tool in the extrapolation of efficacy in pediatric medicine. Based on the introducing of pediatric research features, this paper illustrates the basic concepts and framework of Bayesian statistics, introduces power priors, mixed priors and meta-analysis predictive priors, as well as the important role of simulation technology in Bayesian statistics. Then, a case study of multiple sclerosis in a pediatric population using robust meta-analysis predictive priors to borrow historical data from adult population is present. Finally, this paper discusses other fields of Bayesian statistics in pediatric medication extrapolation and the key consideration in clinical development.
The United States has passed legislation to promote the development of pediatric drugs, requiring R&D companies to submit pediatric study plan in the early stage of research and development. The purpose is to allow R&D companies to determine the needs of pediatric applications in the early stage of clinical research. The specific requirements of the US Food and Drug Administration on pediatric study plan, including the research strategy, the timing of the research and the content of the submitted data, can be used as a reference for Chinese R&D enterprises. Research and development companies can plan pediatric research as early as possible in early clinical research and development, effectively utilize the strategy of extrapolation from adults to children, communicate with regulatory agencies as early as possible, improve research and development efficiency, and speed up the marketing of pediatric drugs.
Dose selection is a key aspect of pediatric drug development. Getting the right dose for pediatric patients, especially newborns and infants, is critical but poses great scientific, practical, and ethical challenges. In addition, the significant differences in different growth and development stages also have an important impact on pediatric dose selection. On the one hand, adult data have reference significance for pediatric drug dose selection and are an important basis for pediatric drug research design and data analysis. On the other hand, model-informed drug development is widely used in dose exposure-response characterization and optimization of dose selection for pediatric drugs. This paper summarizes and analyzes the experience of pediatric drug dose selection, which will serve as a referance for Chinese pediatric drug developers and the follow-up government regulation and policy makers.
Rivaroxaban granules for oral suspension was approved by FDA in 2021 for the treatment of venous thromboembolism(VTE) and prevention of VTE recurrence in patients under age of 18 years after at least 5 days of initial parenteral anticoagulation treatment. The development of rivaroxaban granules for oral suspension for pediatric indications was based on adult data. Model-informed drug development method was adopted to support the initial dosage selection in pediatric clinical trials, dose adjustment of phase Ⅱ and Ⅲ clinical trials. This paper analyzes the relative pediatric studies and FDA’s evaluation considerations of rivaroxaban granules for oral suspension, and discusses the application of model-informed drug development in pediatric drug development.
Population pharmacokinetics has been widely used in clinical practice, which is an effective method to optimize individualized drug delivery schemes and clinical evaluation of new drugs. This paper introduces the technical system of drug population pharmacokinetics in pediatric population based on the integration of opportunistic sampling approach, micro sample analysis, quantitative pharmacological model of child development and machine learning. The applications of this technical system to research and development of pediatric drugs and individualized treatment are briefly introduced, hoping to promote the process of drug research and development as well as the rational use of medicines in children.
Antiepileptic drugs(AED) are the cornerstone and first-choice of the treatment for childhood epilepsy. However, due to the difficulty of evaluating efficacy by randomized controlled trials in the pediatric population, the development of new AEDs for children is delayed. This paper reviews the evidence, history and current thoughts of applying extrapolation method into the development of pediatric AEDs. Besides, the extrapolation-based strategies for pediatric clinical trial design are also illustrated. The results show that the efficacy of drugs treating focal onset seizures(FOS) currently could be extrapolated from adults to pediatric patients 1 month of age and older. The pediatric extrapolation plans should include: the development of pediatric formulations, the rational design of pediatric pharmacokinetics(PK) study and long-term safety study, as well as model-informed dose selection for antiepileptic drugs in pediatrics.
Respiratory diseases in children, as common diseases with high morbidity, are closely related to the physiological characteristics of respiratory system in children. Chinese patent medicines have obvious advantages and characteristics in the treatment of respiratory diseases in children, but some problems have limited their clinical use. For example, how to accurately quantify the drug dosage is a difficult problem limiting the development of pediatric drugs. Nowadays, the national policies are released to encourage the drug development of pediatric drugs. This paper intends to analyze the research status of Chinese patent medicines for respiratory diseases in children, and put forwards some personal views on this issue, hoping to provide some references for those involved in the development of Chinese patent medicines for the treatment of respiratory diseases in children.
The proposal of “the evidence system for TCM registration evaluation combining TCM theory, experiences in human use and clinical trials” is conducive to the research and development of Traditional Chinese medicine for children. Regarding to the situations encountered in the medical review, this article puts forward some suggestions and considerations from the perspective of clinical review for the reference of development of pediatric drug of TCM.